Inventor · disambiguated record
Olukayode Sosina
Also filed as: SOSINA OLUKAYODE
8 granted patents·8 pending applications·5 citations·filing 2021–2025
78Inventor score
Top patents by PatentIndex Score
16 records- 0192US11957704B2Methods of treating metabolic disorders and cardiovascular disease with inhibin subunit beta E (INHBE) inhibitorsREGENERON PHARMA·Filed 2022·Granted Apr 16, 2024·2 cites·11 claims
- 0291US11759476B2Methods of treating metabolic disorders and cardiovascular disease with Inhibin Subunit Beta E (INHBE) inhibitorsREGENERON PHARMA·Filed 2022·Granted Sep 19, 2023·2 cites·16 claims
- 0385US11359246B2Treatment of obesity with G-protein coupled receptor 75 (GPR75) inhibitorsREGENERAN PHARMACEUTICALS INC·Filed 2021·Granted Jun 14, 2022·1 cites·29 claims
- 0481US2024252528A1Methods Of Treating Metabolic Disorders And Cardiovascular Disease With Inhibin Subunit Beta E (INHBE) InhibitorsREGENERON PHARMA·Filed 2024·Application pending·0 cites
- 0577US12234460B2Methods of treating decreased bone mineral density with cluster of differentiation 109 (CD109) inhibitorsREGENERON PHARMA·Filed 2023·Granted Feb 25, 2025·0 cites·25 claims
- 0675US2024376471A1Treatment of Liver Diseases With Cell Death Inducing DFFA Like Effector B (CIDEB) InhibitorsREGENERON PHARMA·Filed 2024·Application pending·0 cites
- 0773US2025188473A1Methods Of Treating Liver Diseases With Phosphodiesterase 3B (PDE3B) InhibitorsREGENERON PHARMA·Filed 2024·Application pending·0 cites
- 0872US11891607B2Methods of treating decreased bone mineral density with cluster of differentiation 109 (CD109) inhibitorsREGENERON PHARMA·Filed 2022·Granted Feb 6, 2024·0 cites·18 claims
- 0972US2022184114A1Methods Of Treating Metabolic Disorders And Cardiovascular Disease With Inhibin Subunit Beta E (INHBE) InhibitorsREGENERON PHARMA·Filed 2021·Application pending·0 cites
- 1071US12018259B2Treatment of liver diseases with cell death inducing DFFA like effector B (CIDEB) inhibitorsREGENERON PHARMA·Filed 2021·Granted Jun 25, 2024·0 cites·22 claims
- 1170US12123001B2Methods of treating liver diseases with phosphodiesterase 3B (PDE3B) inhibitorsREGENERON PHARMA·Filed 2022·Granted Oct 22, 2024·0 cites·14 claims
- 1270US11773393B2Treatment of liver diseases with cell death inducing DFFA like effector B (CIDEB) inhibitorsREGENERON PHARMA·Filed 2022·Granted Oct 3, 2023·0 cites·27 claims
- 1366US2022411870A1Treatment Of Obesity With G-Protein Coupled Receptor 75 (GPR75) InhibitorsREGENERON PHARMA·Filed 2022·Application pending·0 cites
- 1462US2025236873A1Methods Of Treating Decreased Bone Mineral Density With Cluster Of Differentiation 109 (CD109) InhibitorsREGENERON PHARMA·Filed 2025·Application pending·0 cites
- 1559US2023021584A1Methods Of Treating Decreased Bone Mineral Density With Kringle Containing Transmembrane Protein 1 (KREMEN1) InhibitorsREGENERON PHARMA·Filed 2022·Application pending·0 cites
- 1657US2023083558A1Treatment of Decreased Bone Mineral Density With Wnt Family Member 5B (WNT5B) InhibitorsREGENERON PHARMA·Filed 2022·Application pending·0 cites
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →